Events
Alport Connect 2025 Meeting
19-20 July, 2025
Chicago, IL
ENYO Pharma is sponsoring and will attend Alport Connect 2025 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.
ENYO Pharma will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
BIO International Convention
16-19 June, 2025
Boston, MA
ENYO Pharma will attend the the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
https://convention.bio.org/bio-2025
7th CKD Summit – Chronic Kidney Disease Drug Development
17-19 March, 2025
Boston, MA
ENYO Pharma will attend the 7th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
https://ckd3-summit.com/
J.P. Morgan week and WuXi Global Forum 2025 in San Francisco
13-16 January, 2025
San Francisco, CA, USA
ENYO Pharma will in San Francisco for the J.P Morgan week to reconnect with global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
ENYO Pharma will also take the opportunity to host an executive roundtable at WuXi-Global-Forum-2025 on the 14th of January to share our progress in drug development with Vonafexor in kidney diseases.
4th Rare & Genetic Kidney Disease Drug Development Summit
10-12 December 2024
Boston, MA, USA
ENYO Pharma will attend for the first time the 4th Rare & Genetic Kidney Disease Drug Development Summit that will be held in Boston, USA. The event will bring together industries, academic KOLs, and patient advocacy nephrology communities to discuss acceleration of clinical advancements in orphan kidney disease populations.
ENYO Pharma will present the ongoing ALPESTRIA-1 Phase 2 clinical trial with Vonafexor in patients with Alport syndrome.
Latest Press Release 